Our results imply a direct role of the ITCH-UBE4B complex in responses of neuroblastoma cells to HDAC inhibition, suggesting that the ITCH-UBE4B complex plays a critical role in responses of neuroblastoma to therapy and suggesting a potential mechanism underlying the significant association of UBE4B expression with neuroblastoma patient outcomes. Here, ITCH is linked to neuroblastoma.